07:00 Wed 20 Jan 2021
Alliance Pharma PLC - Full Year Trading Update
For immediate release |
|
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Full Year Trading Update
Strong performance from Consumer Healthcare brands with very strong cash generation
Recent acquisition of Amberen™ set to enhance growth as Alliance's second largest brand
Alliance Pharma plc (AIM: APH), the international healthcare group, announces its unaudited trading update for the year ended
As expected, Group see-through revenues1 for 2020 were down 5% on the prior year at
Notwithstanding the challenges of the pandemic, our Consumer Healthcare brands continued to perform strongly, with total Consumer Healthcare revenues up 1% to
Free cash flow for the year remained very strong at
The acquisition of Biogix has brought Amberen into the Group, a highly successful and fast-growing brand for the relief of menopause symptoms. The acquisition creates scale in the Group's business in the US and is expected to be earnings enhancing in FY 2021 and significantly earnings enhancing from FY 2022.
Peter Butterfield, Chief Executive Officer of Alliance, commented:
"The Group continued to deliver a robust operational and financial performance in the second half of 2020, despite the ongoing challenges of the pandemic. Whilst top line revenue growth has been constrained overall, our Consumer Healthcare business has performed well given the market backdrop and we have seen some strong performances from a number of our brands, in particular Kelo-cote.
"Our free cash flow has remained very strong, enabling us to pay down more of our debt ahead of completing the Biogix acquisition close to the end of the year.
"We're particularly pleased that we managed to complete such a large and strategically significant acquisition at the end of 2020, in addition to maintaining the performance of the base business as we navigated our way through the challenges of COVID-19.
"As we progress into 2021, we look forward to regaining the strong momentum and revenue growth of recent years, and to benefiting from the additional growth opportunities that Amberen brings into the Group."
1 See-through revenue includes sales from Nizoral™ as if they had been invoiced by Alliance. Under the terms of the transitional services agreement with Johnson & Johnson (J&J), Alliance receives the benefit of the net profit on sales of Nizoral from the date of acquisition up until the product licences in each of the Asia-Pacific territories transfer from J&J to Alliance. Revenue for 2020 on a statutory reported basis is expected to be
2 Adjusted net debt / enlarged Group EBITDA, calculated using pro forma EBITDA on a trailing 12 month basis
For further information:
Alliance Pharma plc |
+ 44 (0)1249 466966 |
Peter Butterfield, Chief Executive Officer |
|
Andrew Franklin, Chief Financial Officer |
|
|
|
Buchanan |
+ 44 (0)20 7466 5000 |
Mark Court / Sophie Wills / Hannah Ratcliff |
|
|
|
Numis Securities Limited |
+ 44 (0)20 7260 1000 |
Nominated Adviser: Freddie Barnfield / Huw Jeremy |
|
Corporate Broking: James Black |
|
Investec Bank plc |
+ 44 (0) 20 7597 5970 |
Corporate Finance: Daniel Adams |
|
Corporate Broking: Patrick Robb |
|
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.
We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.
Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE